Please assess the completion status of the following clinical trial:

Trial Title: CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Relapsed and refractory CD19 positive B-cell acute malignancies with:~   * Relapsed after competed remission, could not get competed remission after at more than 1 course of chemotherapy (including MRD≥0.1%);~  * MRD≥0.1% after allogeneic hematopoietic stem cell transplantation(HSCT), or recurrence after complete remission or MRD ≥ 0.1% after HSCT;~  * Refractory: at least two courses of chemotherapy did not achieve complete remission or MRD ≥ 0.1%;~2. Patients must have evaluable evidence of disease, including minimal residual disease (MRD);~3. Ph + patients who meet the following criteria can register:Failure to tolerate TKI or TKI treatment failure, or failure to transplant;~4. Ages 1 to 70 years, including boundary values;~5. ECOG score 0-3 points;~6. Women of childbearing age (15-49 years old) must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 3 months after discontinuation of treatment during the study period not pregnant inside.~Exclusion Criteria:~1. patients with organ failure:~   * Heart: NYHA heart function grade III or IV ;~  * Liver: Grade C that achieves Child-Turcotte liver function grading;~  * Kidney: kidney failure and uremia;~  * Lung: symptoms of respiratory failure;~  * Brain: a person with a disability;~2. Active infections that are difficult to control;~3. Human immunodeficiency virus (HIV) positive;~4. Liver and kidney function: total bilirubin \> 5 × ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \> 5 × ULN, serum creatinine clearance rate 60mL / min;~5. GVHD ≥ 2 or receiving anti-GVHD treatment;~6. Received allogeneic cell therapy within 4 weeks, such as donor lymphocyte infusion(DLI);~7. Subject received anti-tumor treatment (chemotherapy, mAb, or hormone) for less than 1 week;~8. Central nervous system leukemias that is symptomatic or uncontrolled by systemic chemotherapy and intrathecal chemotherapy (a large number of tumor cells in CSF, white blood cell count \>15WBCs/mL);~9. intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation;~10. pregnant or lactating women;~11. The patient does not agree to use effective contraception during the treatment period and for the next 3 months;~12. Patients who participate in other clinical studies at the same time;~13. The investigator believes that there are other factors that are not suitable for inclusion or influence the subject's participation or completion of the study.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CD19-STAR-T cells (Type: EXPERIMENTAL): CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).